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Abstract
Bezielle (BZL101) is a candidate oral drug that has shown promising efficacy and excellent safety in the early phase clinical
trials for advanced breast cancer. Bezielle is an aqueous extract from the herb Scutellaria barbata. We have reported
previously that Bezielle was selectively cytotoxic to cancer cells while sparing non-transformed cells. In tumor, but not in
non-transformed cells, Bezielle induced generation of ROS and severe DNA damage followed by hyperactivation of PARP,
depletion of the cellular ATP and NAD, and inhibition of glycolysis. We show here that tumor cells’ mitochondria are the
primary source of reactive oxygen species induced by Bezielle. Treatment with Bezielle induces progressively higher levels
of mitochondrial superoxide as well as peroxide-type ROS. Inhibition of mitochondrial respiration prevents generation of
both types of ROS and protects cells from Bezielle-induced death. In addition to glycolysis, Bezielle inhibits oxidative
phosphorylation in tumor cells and depletes mitochondrial reserve capacity depriving cells of the ability to produce ATP.
Tumor cells lacking functional mitochondria maintain glycolytic activity in presence of Bezielle thus supporting the
hypothesis that mitochondria are the primary target of Bezielle. The metabolic effects of Bezielle towards normal cells are
not significant, in agreement with the low levels of oxidative damage that Bezielle inflicts on them. Bezielle is therefore a
drug that selectively targets cancer cell mitochondria, and is distinguished from other such drugs by its ability to induce not
only inhibition of OXPHOS but also of glycolysis. This study provides a better understanding of the mechanism of Bezielle’s
cytotoxicity, and the basis of its selectivity towards cancer cells.
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Introduction
Bezielle(BZL101,FDAIND#59.521)isan extractprepared from
the aerial parts of herb Scutellaria barbata that has anti-cancer
properties. S. barbata extract was shown to have cytotoxic activity
against various tumor cell lines in vitro [1,2,3,4,5,6,7,8,9,10] and
antitumoractivityinvivo[11,12,13]inmodelsofrenal,hepatocellular
and prostate carcinoma. More importantly, two early stage clinical
trials with Bezielle showed promising efficacy and excellent safety for
treatment of advanced breast cancer [14,15]. In the phase Ia clinical
trial sixteen patients, all of which went through multiple treatment
therapies prior to enrollment were evaluable for response. Four
patients had stable disease for .90 days (25%) and 3/16 had SD for
.180 days (19%). Five patients had objective tumor regression [15].
Subsequent small scale escalation trial with an improved formulation
of Bezielle showed a similarly promising efficacy [14]. The need for
new drugs to curb morbidity and mortality of metastatic cancers
cannot be overemphasized. In particular, orally available drugs with
less toxicity are urgently needed. Bezielle fulfills these unmet needs,
and larger clinical studies to provide more definitive data regarding
safety and efficacy are planned.
We have reported previously that Bezielle kills selectively tumor
cells while sparing non-transformed cells in vitro [8,15]. This
selectivity might account for its superior safety profile demonstrat-
ed in early clinical trials when compared to other approved
cytotoxic agents. To date, analyses of the cellular effects of Bezielle
have revealed that the basis for Bezielle’s selectivity is the
induction of high levels of reactive oxygen species (ROS) in tumor
cells that is strongly attenuated in normal cells. ROS induced by
Bezielle cause extensive DNA damage and hyper activation of
PARP-1 in tumor cells. Significantly, Bezielle induced a modest
DNA damage in non-transformed cells that was repaired and did
not involve a hyper activation of PARP [8]. In tumor cells,
activation of PARP depleted NAD+ and ATP that are used to
synthesize poly-ADP ribose for PAR-ylation of a number of
cellular proteins involved in DNA damage repair, transcriptional
control and regulation of cell cycle [16,17,18]. Depletion of
cytosolic NAD+ is most likely the cause of the subsequent selective
inhibition of glycolysis [19,20,21] that is observed in Bezielle
treated tumor but not in normal cells [8]. Inhibition of glycolysis as
well as collapse of redox status (manifested in depletion of NADPH
and GSH in tumor cells treated by Bezielle) are the likely cause of
cell death triggered by Bezielle. Indeed, our results show that
Bezielle induces mainly necrotic death [8] that is known to be
associated with the hyperactivation of PARP-1 [21,22,23]. A
recent detailed combined proteomic and metabolomic analysis of
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oxidative stress damage followed by redistribution of metabolic
fluxes [24]. Specifically, three families of enzymes involved in
maintenance of redox potential were affected by Bezielle:
glutathione- and thioredoxin-related proteins and peroxiredoxins.
The largest subset of proteins affected by Bezielle were those
involved in metabolic pathways, including glycolysis, Krebs cycle
and fatty acid metabolism. These data support the hypothesis that
Bezielle critically affects tumor cells metabolism through oxidative
damage.
In this study, we have further analyzed the mechanisms of
Bezielle induced cell death and its selectivity. We report that
mitochondria are the primary cellular target of Bezielle, and the
previously described cellular consequences of treatment with
Bezielle are triggered through the effects of this botanical extract
on mitochondria. By examining the metabolic effects of Bezielle
we have found that Bezielle inhibits not only glycolysis but also
oxidative phosphorylation, thus compromising both cellular
energy production pathways.
Materials and Methods
Reagents and antibodies
Bezielle extract was prepared as described earlier for the clinical
grade material [15]. Briefly, the dried raw herb was ground to a
fine powder, added at a ratio 1:10 (weight to volume) to pre-
warmed water and simmered at 80uC for 30 minutes. The
supernatant was separate from the insoluble solids by centrifuga-
tion at 5,000 rpm, and subject to a freeze-drying. The resulting
powder was dissolved in water at 50 mg/ml and sterile filtered
prior to use.
Diphenylene iodonium (DPI), N-acetyl-cystein, apocynin,
FCCP (p-trifluoromethoxy carbonyl cyanide phenyl hydrazone),
antimycin A and other chemicals were purchased from Sigma.
Fluorescent indicators of ROS CM-H2DCFDA and MitoSox Red
were from Molecular Probes/InVitrogen. Antibodies to PAR were
from Becton-Dickinson, to NOX4 from Epitomics, to subunit 2 of
the mitochondrial complex IV from Mitosciences, to LC3 from
Abgent, and to SQSTM from Cell Signaling.
Cell culture and treatments
All cell lines were obtained from the ATCC. MDAMB231 were
propagated in RPMI with 10% FCS. MCF10A were propagated
in DME/F12 with 5%FCS, 50 mg/ml pituitary extract, 10 mg/ml
insulin, 0.5 mg/ml hydrocortisone and 0.02 mg/ml EGF (Sigma).
Hs578T and SKBr3 cells were cultured in DMEM with 10% FCS.
Preparation of the aqueous extract of Bezielle was described earlier
[8]. Cells were treated with Bezielle at 250 mg/ml (dry weight per
volume), unless otherwise indicated in the Legends to Figures, or
with water (labeled as ‘‘untreated’’ throughout the paper). All
treatments with Bezielle were done in full growth media lacking
pyruvate.
Measurement of the ROS
Fresh stocks of ROS indicators CM-H2DCFDA and MitoSox
Red were prepared in DMSO at a concentration of 0.5 mM and
diluted into warm growth media to the concentration of 2.5 mM.
The medium containing one of the indicator dyes was added to
cells. After incubating the cultures with the probes for 20 minutes,
cells were washed with PBS, treated with trypsin and harvested for
analysis by FACS. Fluorescence from CM-H2DCFDA was
collected on FL1 channel, and for MitoSox Red on FL2 channel.
Each experiment included cells that were not subjected to treatment
with Bezielle. The fluorescence levels of these untreated cells were
assigned an arbitrary value of 1, and fluorescence of Bezielle treated
cells is shown in Figures as ‘‘fold increase’’ over untreated cells.
Lentivirus - mediated siRNA and gene expression
For NOX4 silencing, six shRNA constructs in the LKO plasmid
vector were purchased from Open Biosystems/Thermo. Viruses
were produced in HEK293 cells according to manufacturer’s
instructions and used to transduce cells, followed by selection in
pre-determined concentrations of puromycin.
Measurements of cell viability, cell numbers and
apoptosis
Cell viability was determined using CCK-8 kit (Dojindo). Cell
death analysis was done using the Annexin V/propidium iodide
staining followed by flow cytometry. Cells were collected by
trypsinization into their culture media, washed with PBS and
stained with Annexin V- FITC (BioVision) and propidium iodide
(PI), and analyzed immediately after a 5 minute incubation using
the CellQuest software on the FACScan (Becton Dickinson). ATP
levels were quantified with ATP Bioluminescence assay kit HS II
(Roche Applied Science).
Quantification of reduced glutathione using fluorescent
probe monobromobimane
Cells in 96 well plates were treated as desired, the treatment
media was removed and substituted with media containing 8 mM
monobromobimane(mBB).Fluorescencewasreadonaplatereader
with filters set at excitation of 360 nM and emission at 460 nM.
Western blot analysis
Whole cell lysates were electrophoresed on SDS-PAGE and
transferred to nitrocellulose membranes. Membranes were blotted
with antibodies at recommended concentrations overnight at 4uC
and the bound primary antibodies were detected using peroxidase-
conjugated secondary antibodies. Blots were developed using
SuperSignal enhanced chemiluminescence kit (Pierce) and imaged
on Kodak Imager ISR2000.
Comet Assay
Comet assays were performed using the Comet assay kit from
Trevigen according to the manufacturer’s instructions. Briefly, cells
were harvested, washed and resuspended with PBS. The cells were
combined with molten, low melting point agarose at 37uCa n d
pipetted unto Comet slides. The agarose was allowed to solidify at
4uC for 30–40 min, and slides were immersed in cold lysis solution
(Trevigen, Inc.) for 30 min at 4uC. The slides were immersed next
into freshly prepared alkali solution (300 mM NaOH and 1 mM
EDTA) for 20 min and subjected to electrophoresis in the same
alkaline buffer at 15 V (0.5 v/cm) and 300 mA for 25 min. Slides
were rinsed in water and fixed in 70% ethanol for 5 min. After air-
drying, the nuclei were stained with SYBR green (Trevigen, Inc.)
and viewed under a fluorescence microscope. Percentages of cells
withcomets were quantified by two observers blindedto the identity
of the slides. Nuclei were also photographed and analyzed with the
TriTek CometScore image analysis software. Olive tail moment,
defined as the product of percentage DNA in the tail and
displacement between the position of the mean centers of mass in
the heads and tails, was determined for at least 40 cells per sample.
Metabolic analyses with Seahorse XF96 Extracellular Flux
Analyzer
Cells were plated overnight on XF96 PET 96 well plates at
experimentally predetermined numbers (10610
3 cells per well for
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3 cells per well for MCF10A). Metabolic
fluxes were analyzed on Seahorse XF96 analyzer per manufac-
turer instructions as previously described [25]. Basal ECAR
(extracellular acidification rate, in mpH/min), OCR (oxygen
consumption rates, in pMoles O
2/min) and PPR (normalized
proton production rate, in nmol H+/min) values were measured
for 4 cycles. Each cycle consisted of a 3 minutes media mixing
time and a 5 minutes measurements time. After measuring the
basal levels of ECAR and OCR for 4 cycles, the mitochondrial
uncoupler FCCP at 1 mM was automatically injected into the
experimental wells in order to quantify the maximum respiration
capacity, or mitochondrial reserve. Following one cycle of
measurements inhibitor of mitochondrial complex III antimycin
Aa t5mM was injected into the experimental wells, and another
measurement cycle was performed to verify that oxygen
consumption was of mitochondrial origin. Each experimental
point was an average of 6 to 10 replica wells in each experiment,
and experiments were repeated at least 3–4 times. Experimental
data were considered acceptable only when variations in pH
values between mix and measure cycles were less than 0.05–0.1
pH units. This ensured that ECAR data were not artificially
altered by changes in pH values, and in fact closely paralleled
changes in PPR values. Normalization of values obtained in XF96
assays was performed using quantification of cellular DNA on
experimental plates with the CyQuant assay (Promega). All the
XF96 data are expressed as ECAR or OCR values normalized to
DNA content.
Results
The role of mitochondria in the induction of ROS and cell
death by Bezielle
We have reported previously that Bezielle is selectively cytotoxic
to breast cancer cell lines but not to non-transformed cells such as
immortalized mammary cells and primary fibroblasts, which are
relatively resistant to its cytotoxic effect [8]. We have since tested
Bezielle’s cytotoxicity in over two dozens of cancer cell lines and
four different immortalized cell lines and primary cells. We
observed that on average the non-transformed cells are much less
sensitive to Bezielle that cancer cell line (manuscript in
preparation). Figure 1A illustrates these observations with two
cell lines: breast carcinoma line MDAMB231 and immortalized
epithelial line MCF10A. We have observed that the sensitivity to
Bezielle in general does not correlate directly with the proliferation
rate of the cell lines (data not shown). Thus, the proliferation rate
of the non-transformed MCF10A cells is actually somewhat higher
than that of cancer cell lines MDAMB231, and is much higher
that that of other breast cancer cells lines that are sensitive to
Bezielle [8].
The induction of death in cancer cells by Bezielle is a direct
consequence of induction of ROS and oxidative stress, because co-
treatment with antioxidants N-acetyl-cystein (NAC) or pyruvate
inhibited DNA damage and cell death [8]. We aimed to identify
the cellular sources of the Bezielle-induced ROS. Cell lines were
treated with Bezielle for different times and loaded with cell-
permeable indicators of ROS CM-H2DCFDA that becomes
fluorescent in response to peroxide-type oxygen radicals [26], or
MitoSox Red, highly selective for mitochondrial superoxide [27].
We have observed a gradual time dependent increase in ROS in
breast cancer cell lines MDAMB231 and SKBr3, but not in
MCF10A cells after treatment with Bezielle (Figure S1). Figure 1B
illustrates ROS levels at 30 minutes and 6 hours after treatment.
Data are expressed as fold increase of fluorescence over that seen
in untreated cells loaded with the fluorescent indicator.
MDAMB231 produced more ROS than MCF10A cells already
after the first 30 minutes of incubation with Bezielle, but with time
the difference in ROS levels induced in the two cell line became
increasingly more pronounced. At six hours of treatment both
peroxide and mitochondrial superoxide were increased by
approximately five and six-fold, respectively, in MDAMB231
cells. The increase in ROS levels in MCF10A was much more
modest, and barely exceeded two fold over the basal ROS levels
even after 6 hours of treatment (Figure 1B). It is possible that the
continuous accumulation of ROS in tumor cell lines is directly
relevant to their sensitivity to Bezielle.
These results posed a question regarding the nature of peroxide
type radicals induced by Bezielle: namely, does Bezielle induce
both peroxide and superoxide, or is peroxide merely a conversion
product of mitochondrial superoxide? Considering that superoxide
is a short lived species of reactive oxygen, the high levels of it
observed at 6 hours are likely due to continuous generation by
mitochondria. The correspondingly high levels of peroxide type
ROS could be resulting from the conversion of superoxide to
peroxide by superoxide dismutase.
To examine the role of mitochondrial superoxide in cell death
induced by Bezielle, we have employed a well-tested method of
disabling mitochondrial respiration by culturing cells in presence
of ethidium bromide. After culture of cells in low concentration of
ethidium bromide for 6 weeks, these cells (MDAMB231Rho-0)
have lost expression of mitochondrial proteins encoded in
mitochondrial genome as seen in Figure 1C, rendering mitochon-
dria not functional. This was also confirmed by examining
mitochondrial oxygen consumption of MDAMB231 Rho-0 cells,
which was greatly reduced (see below, Fig. 6). The Rho-0 cells
were treated with Bezielle, and examined for induction of ROS
and cell death. Figure 1D shows that the MDAMB231 Rho-0
cells, as expected, do not generate mitochondrial superoxide in
response to Bezielle, confirming the role of mitochondrial electron
transport in the induction of ROS by Bezielle. Levels of peroxide
generated in Bezielle treated Rho-0 cells were somewhat increased
at 30 minutes of incubation, but showed no further increase over
time (Figure 1D), strongly supporting our suggestion that high
peroxide levels could be due largely to conversion of mitochondrial
superoxide. Most importantly, the MDAMB231 Rho-0 cells were
very strongly protected from cell death induced by Bezielle
(Figure 1E) suggesting the pivotal role of mitochondria in death of
tumor cells treated with Bezielle.
Potential other cellular sources of ROS induced by
Bezielle
The data described above heavily implicate the mitochondrially
generated superoxide in Bezielle cytotoxicity. However, while
induction of mitochondrial superoxide by Bezielle was entirely
prevented in Rho-0 cells, the CM-H2DCFDA detectable peroxide
type ROS, as mentioned above, were not completely abolished
(Figure 1D). We have considered the possibility that some other
cellular enzymes capable of producing peroxide or extra-
mitochondrial superoxide may contribute to the oxidative stress
caused by Bezielle. We have used inhibitors of several cellular
enzymes that produce ROS: diphenylene iodonium (DPI) and
apocynin for inhibition of NADPH oxidases; allopurinol to inhibit
xantine oxidase, nordihydroguaiaretic acid (NDGA) to inhibit
LOX, and Nitro-L-arginine methyl ester (L-NAME) to inhibit
nitric oxide synthase. MDAMB231 cells were treated with Bezielle
in presence of each of these inhibitors, and the extent of cell death
as well as ROS induction was quantified in relevant assays. None
of the inhibitors reduced ROS levels in Bezielle-treated cells with
the exception of DPI (not shown and Figure 2A). Similarly, with
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death (not shown).
Figure 2A shows inhibition of both peroxide type ROS and
mitochondrial superoxide production by DPI in Bezielle-treated
cells. The observed strong inhibition of mitochondrial superoxide
by DPI was unexpected, since inhibition of NADPH oxidases
(NOX) should not have a profound effect on mitochondria, even
though some published studies suggest the existence of a cross-talk
between Nox activation and mitochondrial production of
superoxide [28,29]. However, DPI was also reported to be a
potent inhibitor of mitochondrial superoxide production probably
through the non-specific inhibition of NADH-ubiquinone oxido-
reductase in mitochondrial complex I [30].
Not surprisingly, inhibition of Bezielle induced ROS production
by DPI had a protective effect on Bezielle-induced cell death
(Figure 2B). Even though DPI alone was somewhat cytotoxic to
cells, it strongly attenuated cell death induced by Bezielle
(Figure 1E). To rule out the possibility that the effects of DPI
Figure 1. Bezielle selectively targets mitochondria of cancer cells to induce cell death. A. Bezielle induces cell death in tumor cells but is
less cytotoxic towards non-transformed mammary cells. Breast cancer cell line MDAMB231 and non-transformed line MCF10A were treated with
Bezielle at the indicated concentrations for 24 hours, and cell viability was quantified using the CCK-8 assay kit. Results are mean 6 S.E. (n=4). B.
Cells were treated with Bezielle at 250 mg/ml for half an hour or 6 hours, loaded with the ROS sensitive probes, and analyzed by flow cytometry for
green (H2DCFDA) or red (MitoSox) fluorescence. Results are expressed as fold increase of fluorescence in treated cells compared to untreated probe-
loaded cells. Results are mean 6 S.E. (n=3). Significant differences between MDAMB231 and MCF10A are indicated (** P,0.01). C. Western blot
analysis of MDAMBRho-0 cells selected in low concentration of ethidium bromide confirms the elimination of the mitochondrially encoded subunit 2
of the respiration complex IV, and therefore inhibition of OXPHOS. D, Analysis of ROS induction in Rho-0 cells performed as described in B. E. Analysis
of cell death induction by Bezielle in Rho-0 cells performed as described in A. Significant differences between the indicated groups are indicated
(*P,0.05; ** P,0.01).
doi:10.1371/journal.pone.0030300.g001
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examined effects of DPI on cell death in an additional breast
carcinoma cell line SKBr3. The SKBr3 cells showed an even
stronger protection by DPI than MDAMB231, indicating that the
protective effect of DPI towards Bezielle is not an isolated
phenomenon (Figure 2C).
We have therefore examined if the non-phagocytic NOX known
to be expressed in breast tumors [29,31] could be involved in
Bezielle cytotoxicity. The results of these experiments are shown in
Figure S2. Briefly, even though NOX4 appears to be upregulated
by Bezielle in tumor cells, partial silencing of its expression in
MDAMB231 cells indicated that NOX4 produced ROS do not
play a significant role in cell death induced by Bezielle.
The question, however, still remained about the mechanism of
the mitochondrial ROS reduction by DPI. We have found that
DPI, even at the low concentration used here, inhibits mitochon-
drial respiration (see below), and thus, in effect, acts as inhibitor of
OXPHOS, similar to the ablation of mitochondrial function in
Rho-0 cells.
Induction of DNA damage
Bezielle induces oxidative DNA damage that is critical for its
ability to selectively kill cancer cells [8]. We have examined how
lack of functional mitochondria and treatment with DPI affect
induction of DNA damage by Bezielle in MDAMB231 cells. Cells
treated with Bezielle were analyzed by Comet assay for two
parameters of DNA damage: percent of cells with damaged DNA,
and the olive moment (reflecting the extent of DNA damage in
individual cells). As seen in Figure 3A, treatment with Bezielle led
to progressively increasing numbers of cells with DNA damage for
up to 6 hours. After that time point, dead cells with partially
degraded or severely damaged DNA started accumulating, making
the comet quantification difficult. Analysis of the comet tail
moment (Figure 3B) revealed a steep increase of DNA damage per
cell induced by Bezielle over time. The increasing amount of DNA
damage per cell in a time-dependent manner correlates well with
the observed increase in ROS levels (Figure 2B).
In MDAMB231 Rho-0 cells, less than half of the cells in the
treated population showed the presence of DNA damage even
after 6 hours (Figure 3A), and olive moment analysis detected low
levels of DNA damage per cell that did not increase over time
(Figure 3B). Presence of DPI had a limited effect on the number of
cells with DNA damage, but had a strong inhibitory effect on the
increase in DNA damage per cell over time. The weak effect of
DPI on the number of cells with DNA damage might be related to
the weaker protective effect of DPI against Bezielle induced death
compared to protection in Rho-0 cells (Figure 1E and 2B).
We have also analyzed Bezielle induced DNA damage in
MCF10A cells, and have observed that even in the continuous
presence of Bezielle in the growth media, DNA damage in these
cells was gradually reduced over time (Figure 3C). We suggest that
much lower levels of ROS induced in MCF10A cells (Figure 1B)
led to limited levels of DNA damage which was successfully
repaired. This could explain the time dependent reduction in the
DNA damage in MCF10A cells.
We have documented hyper activation of PARP in tumor cells
treated with Bezielle, and its role in the induction of cell death. We
have examined if PARP was activated in MDAMB231 Rho-0 cells
or in DPI-treated cells. As shown in Figure 3D, PARP was strongly
activated in MDAMB231 cells. In Rho-0 cells, PARP activation
was significantly less robust. In DPI-treated cells, Bezielle activated
PARP to levels in between these observed in control versus Rho-0
cells (Figure 3D). PAR-ylation of proteins in MDAMB231 cells
continued for hours after the start of treatment with Bezielle, but
in Rho-0 cells the activation of PARP was not only much weaker,
but also transient in nature (Figure 3E). Altogether, the data above
show that lack of functional mitochondria strongly inhibited
induction of ROS, DNA damage, activation of PARP and cell
death by Bezielle. We therefore conclude that mitochondria are
the primary cellular target of Bezielle.
Cancer cells treated with Bezielle undergo a collapse of
oxidative defense system
Previously published analysis of the transcriptional changes
induced by Bezielle in tumor cells [8] indicated that the
glutathione redox system is engaged in the cellular response to
Bezielle, a conclusion supported by the recent proteomic and
metabolomic analyses [24]. Thus, elevated expression of cystathi-
Figure 2. NOX inhibitor DPI inhibits induction of ROS and cell death by Bezielle. A. MDAMB231 cells were incubated with Bezielle in
absence or presence of 0.75 mM DPI for 6 hours and examined for ROS production. B. Cell death in MDAMB231cells treated with Bezielle for 24 hours
in absence or presence of 0.75 mM DPI. All results in A and B are mean 6 S.E. (n=3). Significant difference (*P,0.05; ** P,0.01) between the
indicated groups are shown. C, Cell death in breast carcinoma cells SKBr3 treated with Bezielle for 24 hours in absence or presence of 0.75 mM DPI.
Results are average of two experiments.
doi:10.1371/journal.pone.0030300.g002
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were observed in Bezielle treated tumor cells but not in non-
transformed cells. Therefore, we examined levels of reduced
glutathione (GSH) in cells treated with Bezielle. The results in
Figure 4A show a strong and rapid decline of GSH in
MDAMB231 cells. Levels of GSH were somewhat reduced in
MCF10A, but the decline in GSH was relatively mild and not
sustained. At longer incubation times, GSH was almost entirely
depleted in MDAMB231 cells (not shown). GSH is an important
antioxidant, and conversion of oxidized GSH (GSSG) to GSH
requires NADPH. We have therefore examined levels of NADPH
in cells treated with Bezielle. Even after only 4 hours (Figure 4B)
there was a profound depletion of NADPH in MDAMB231 cells.
Evidently, the redox balance in MDAMB231 cells, but not
MCF10A cells treated with Bezielle was undergoing a rapid
collapse. As has already been reported by us [8], levels of ATP
were also quickly depleted in MDAMB231 cells (Fig. 4B). Rapid
loss of redox potential and energy is likely to play a major role in
the selective cytotoxicity of Bezielle towards tumor cells supporting
active OXPHOS.
Metabolic effects of Bezielle
We have described earlier a strong and selective inhibitory effect
of Bezielle on glycolysis in tumor cells, reflected in a strong
reduction of lactate production and activity of glycolytic enzymes
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and lactate
dehydrogenase [8]. Considering the data described above that
implicate mitochondria as primary target of Bezielle, we have now
examined the effect of Bezielle on mitochondrial OXPHOS. We
used the extracellular analyzer of metabolic fluxes XF9 (Seahorse
BioSciences), which monitors glycolysis and mitochondrial OX-
PHOS in real time and in a non-invasive manner.
Figure 4C shows the basal rates of mitochondrial respiration (or
oxygen consumption rate, OCR) and glycolysis (extracellular
acidification rate, ECAR, a measure of lactate production) in
MDAMB231 cells and in MCF10A cells. The respiration rates
were somewhat higher in MCF10A cells perhaps reflecting their
higher reliance on OXPHOS for energy production. The results of
metabolic flux analyses of MDAMB231 and MCF10A cells treated
with Bezielle for four hours are summarized in Figure 4D. A
strong inhibition of both mitochondrial respiration and glycolysis
Figure 3. Bezielle induced DNA damage is alleviated in cells lacking functional mitochondria. A. MDAMB231 control cells (MM231),
MDAMB231 Rho-0 variant (RHO-), or MDAMB231 cells in presence of DPI (+DPI) were treated with Bezielle for the times indicated and subjected to
alkaline Comet assay analysis. Results are shown as percentages of cells forming comets, mean 6 S.E. (n=3). Significant differences (*P,0.05;
** P,0.01) between the Rho-0 and control groups, and between DPI-treated and control groups are shown. B. Same experiments as in A, but the
results shown are mean olive moments of the comets induced by Bezielle in three cell populations. At least 50 comets were analyzed per each time
point in four separate experiments. Significant differences (**P,0.01) were observed between control cells and both Rho- and DPI-treated groups.
C. Percentages of MCF10A cells showing DNA damage at different times after incubation with Bezielle, results are mean 6 S.E. (n=3). Significant
differences (*P,0.05; ** P,0.01) between cells treated for 30 minutes compared to both 2 and 6 hours are shown. D. Western blot analysis of PARP
activation (PAR) in the indicated cells treated with Bezielle for 1 hour. Also shown are the lack of expression of the mitochondrially encoded protein
(complex IV subunit II) in Rho-0 cells, expression of mitochondrial protein VDAC encoded in nuclear DNA, as well as b-actin as a loading control.
E. MDAMB231 cells and MDAMB231-Rho-0 cells were treated with Bezielle for the indicated times and analyzed for presence of poly-ADP-ribosylated
proteins. b-actin serves as a loading control.
doi:10.1371/journal.pone.0030300.g003
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effects of Bezielle on MCF10A cells were relatively minor, even
though a consistent slight reduction in metabolic rates was
observed. We have also examined the effects of Bezielle on proton
production rate (PPR), a measure of glycolytic activity available in
the Seahorse instrument that calculates proton release rates rather
than changes in pH. PPR under variable setting in the instrument
is independent of changes in pH. Figure S3A shows that, similar to
ECAR, PPR is strongly inhibited by Bezielle in MDAMB231 and
Hs578T tumor cells, but not significantly in MCF10A. We
conclude that Bezielle inhibits both cellular energy-producing
pathways selectively in tumor cells but not in non-transformed
cells.
We have next examined how treatment with Bezielle affects the
mitochondrial reserve capacity in MDAMB231 cells. Reserve
capacity is a measure of mitochondrial energy reserve [32].
Irreversible depletion of mitochondrial reserve capacity would lead
to cell death [33]. Metabolic fluxes were measured in untreated
and Bezielle treated MDAMB231 cells before and after injection
of the mitochondrial uncoupler FCCP into XF96 assay media
followed by the inhibitor of the respiration complex III antimycin
A. By uncoupling mitochondrial respiration from ATP synthesis,
addition of FCCP allows the measurement of the mitochondrial
reserve capacity. As seen in Figure 5A, in untreated MDAMB231
cells oxygen consumption is significantly increased after injection
of FCCP, indicating that these cells could increase their
mitochondrial respiration if conditions demand so. Following
injection of complex III inhibitor antimycin, cell respiration is
inhibited, confirming that the observed increase of OCR after
FCCP addition is a true indicator of mitochondrial ability to
respire above the levels needed to support energy demand. Cells
treated with Bezielle for 4 hours fail to respond to FCCP by an
increase in respiration altogether, which shows that the mito-
chondrial reserves are depleted. Treatment of healthy cells with
FCCP triggers a fast increase in glycolysis (measured as either
ECAR or PPR) to compensate for the failure of the mitochondrial
energy production, and is observed in untreated MDAMB231 cells
(Figure 4B and Figure S3B). However, in Bezielle treated cells
Figure 4. Bezielle disrupts redox and energy status in breast cancer cells. A. Bezielle depletes cellular store of reduced glutathione. Levels
of GSH were monitored in cells using monobromobimane as described in Materials and Methods. The basal levels of GSH in untreated MDAMB231
cells were 32611% higher than in MCF10A cells. B. Levels of NADPH and ATP in cells treated with Bezielle for 4 hours. Results in A and B are mean 6
S.E. (n=3). Significant differences (* P,0.05, ** P,0.01) between MCF10A and MDAMB231 are shown. C. Basal levels of OXPHOS (OCR) and glycolysis
(ECAR) in untreated MDAMB231 cells and MCF10A cells. OCR values are in pMoles O2/min, and ECAR values are in mpH/min. Extracellular flux was
analyzed using XF96 as described in Materials and Methods. Results are mean and S.E. of five experiments. D. Analysis of changes in OCR and ECAR in
cells treated with Bezielle for 4 hours. Results are mean and S.E. of five experiments. Significant differences (** P,0.01) between Bezielle treated and
untreated cells are indicated.
doi:10.1371/journal.pone.0030300.g004
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increase in response to FCCP. Same experiments performed with
MCF10A showed a nearly complete lack of an effect of Bezielle on
mitochondrial reserve capacity in these cells (not shown).
Metabolic effects of Bezielle were also examined in Hs578T
cells. Analysis of these cells showed that they are significantly more
glycolytic than MDAMB231 cells (Figure S3A). The proton
production rate (PPR) in untreated Hs578T cells was much higher
than in MDAMB231 cells, demonstrating a strong preference for
glycolysis in Hs578T (Figure S3A). Nevertheless, Bezielle had
similar effect on metabolism of Hs578T cells, i. e., reduction in
both OXPHOS and glycolytic activity (Figure 5C and 5D).
To obtain further support for the hypothesis that mitochondria
are the primary target of Bezielle, in particular as related to the
observed inhibition of glycolysis, we monitored the bioenergetic
changes induced by Bezielle in the Rho-0 variant of MDAMB231
cells, as well as in cells treated with DPI. As shown above, both are
quite resistant to the cytotoxic effects of Bezielle (Figure 1E and
2B). The basal rate of oxygen consumption (OCR) was predictably
low in Rho-0 cells, and almost as low in cells acutely treated with
DPI (Figure 6A). It is most likely, therefore, that the resistance of
DPI-treated cells to Bezielle could be related to the DPI-induced
inhibition of mitochondrial respiration, in essence mimicking the
absence of respiring mitochondria in Rho-0 cells. The already low
residual respiration levels in the Rho-0 and DPI-treated cells were
not further affected by Bezielle, whereas a strong inhibition of
OCR was seen in Bezielle-treated control MDAMB231 cells
(Figure 6A).
Examination of glycolysis showed a modest increase in
untreated Rho-0 and DPI-treated cells, probably due to the
compensatory cellular response of cells where OXPHOS is
inhibited [34]. The glycolytic rate in control MDAMB231 cells
was reduced by about half after 4 hours of treatment with Bezielle,
but glycolysis was not significantly affected by Bezielle in Rho-0 or
Figure 5. Bezielle suppresses both energy producing pathways in breast cancer cells. A. Oxygen consumption (OCR, (pMoles O
2/min))
and reserve capacity in MDAMB231 cells treated with Bezielle at 300 mg/ml for four hours or left untreated. After measuring ECAR and OCR for four
cycles (of which last three are shown), 1 mM FCCP was injected for one measurement cycle followed by injection of 5 mM of antimycin A and another
mix-measure cycle. B, ECAR (mpH/min) measurements in same experiments as described in A. In all experiments quantifying metabolic flux each
experimental point is a mean6 S.E. of normalized values measured in 8 to 10 replica wells. Results in A and B are mean 6 S.E. of three independent
experiments. C and D. Effect of Bezielle on metabolism of breast cancer cell line Hs578T. Cells were treated with Bezielle at 300 mg/ml for 5 hours and
analyzed in the Seahorse XF96 for mitochondrial respiration (OCR) and glycolytic activity (ECAR) as described above for MDAMB231 cells.
doi:10.1371/journal.pone.0030300.g005
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presence of respiring mitochondria. A. MDAMB231 cell (con) in absence and presence of DPI, and Rho-0 variant cells were treated with Bezielle
or water (UT) for 4 hours. The basal levels of OCR were measured in XF96 analyzer. B. Same as in A, for glycolytic activity, ECAR. Results are mean 6
S.E. (n=3). C. Respiration and mitochondrial reserve capacity (OCR, pMoles O
2/min) in untreated MDAMB231 and Rho-0 cells. D. Glycolytic activity
ECAR, (mpH/min) in untreated MDAMB231 and Rho-0 cells. E and F. OCR and ECAR respectively, in same cells treated with Bezielle for four hours.
Shown are results of a representative experiment from three experiments performed.
doi:10.1371/journal.pone.0030300.g006
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lack of mitochondrial respiration protects cells from the metab-
olism-suppressing effects of Bezielle, strongly supporting the
hypothesis that mitochondria are the primary target of Bezielle.
Next, we examined the bioenergetic effects of Bezielle on the
mitochondrial reserve capacity in cells with disabled mitochondrial
respiration. Figures 6C and 6D show the results of these
experiments for untreated Rho-0 versus control cells (DPI-treated
cells are not shown because they behaved very similar to Rho-0
cells). Treatment with the uncoupler FCCP predictably had no
significant effect on OCR or ECAR in Rho-cells (Figure 6C, D).
Obviously, there is no mitochondrial reserve capacity that could
be revealed by uncoupling respiration in non-respiring cells; and,
because FCCP had no effect on OCR in Rho-0 cells, there was no
feedback effect of FCCP on glycolysis in these cells.
The effect of Bezielle on low basal levels of OCR on Rho-0 cells
was very weak, and FCCP addition had almost no effect
(Figure 6E), similar to untreated Rho-0 cells (Fig. 6C). This was
in a marked contrast to control cells, in which OXPHOS was
inhibited by Bezielle, and mitochondrial reserve capacity exhaust-
ed (Figure 6E). Compared to the strong inhibition by Bezielle of
glycolysis in control MDAMB231 cells (Figure 6F), the Rho-0 cells
maintained virtually the same levels of glycolytic activity after
Bezielle addition. It is most likely that the ability of Rho-0 cells to
maintain glycolytic activity in presence of Bezielle is instrumental
in their increased survival. This also strongly suggests that
mitochondrial ROS are the key causative link in the chain of
events induced by Bezielle, including inhibition of glycolysis.
Discussion
In this paper we explored the mechanism of cell death induced
by Bezielle, a candidate anti-cancer botanical drug. Our previous
work described the critical role of ROS and DNA damage in
Bezielle-induced selective death of tumor cells. We have also
documented the severe inhibition of glycolysis and energetic
collapse in tumor cells treated with Bezielle. In this study we have
identified the primary cellular target of Bezielle as mitochondria,
and the mitochondria-produced ROS as the trigger for the
subsequent events leading to the selective death of Bezielle-treated
tumor cells (Figure 7). We presented the following evidence to
support this conclusion: (a) generation of Bezielle-induced ROS is
greatly inhibited in the non-respiring Rho-0 tumor cells lacking
mitochondria or in cells where mitochondrial respiration is
chemically inhibited; (b) inhibition of mitochondrial respiration
suppresses DNA damage and hyper activation of PARP induced
by Bezielle; (c) inhibition of mitochondrial respiration strongly
attenuates inhibition of glycolysis by Bezielle (d) the Rho-0 cells are
resistant to Bezielle cytotoxicity.
We have addressed the possibility that other cellular ROS-
generating sources could contribute to oxidative stress induced by
Bezielle treatment. In particular because Bezielle is a complex
mixture of phytochemicals, we have considered the possibility that
different cellular organelles and processes could be involved. Our
search for other possible cellular ROS generating sources
indicated that DPI is the only one of several different inhibitors
examined that had a protective effect on cell death through
reduction of Bezielle induced ROS. DPI is considered to be a
somewhat selective inhibitor of NADPH oxidases, and we have
therefore explored the role of inducible NOX4 enzyme in Bezielle
induced cell death. This did not produce experimental evidence
supporting the role of NOX4 in Bezielle induced cell death.
Moreover, we have found, as did other investigators before us
[30,35] that DPI is not a selective inhibitor of NOX. A few studies
[30,35] warned against relying too heavily on some of the
published experimental results obtained with DPI, and interpreted
according to the notion that DPI is a selective inhibitor of the
NOX family. We lend a strong support to these warnings here by
showing directly that DPI inhibits mitochondrial respiration. In
the end, it is somewhat ironic that an attempt to explore potential
targets of Bezielle other than mitochondria resulted in a further
confirmation that mitochondrial respiration is the primary target
of Bezielle. Because disabling mitochondrial respiration led to the
inhibition of the destructive cellular changes induced by Bezielle
(ROS, DNA damage and inhibition of glycolysis) we have to
conclude that mitochondria are the primary target of Bezielle.
Bezielle induces remarkably high levels of ROS in tumor cells
that increase progressively for hours after the start of treatment. It
is tempting to speculate that the progressively higher levels of ROS
induced by Bezielle could be in part due to the earlier described
phenomenon known as ‘‘ROS-induced ROS release’’ or RIRR
[36,37]. According to these publications, the initial exposure to
oxidants induces production of cellular ROS that triggers the
opening of mitochondrial channels followed by the collapse of the
mitochondrial membrane potential and a further increased ROS
generation by the electron transfer chain. Generated ROS can be
released into cytosol and trigger RIRR in neighboring mitochon-
dria. This mitochondrion-to-mitochondrion ROS-signaling leads
to a further enhancement in ROS production. It is conceivable
that organelles other than mitochondria could be involved in
RIRR when the initially generated ROS are released into the
cytoplasm.
We have examined ROS induction and cell death in tumor cells
that have been treated with Bezielle for a relatively short time and
Figure 7. A model depicting the mechanism of action of
Bezielle.
doi:10.1371/journal.pone.0030300.g007
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mitochondrial superoxide levels are progressively increasing in
cells for hours after Bezielle was removed (Figure S4). The levels of
ROS in these cells are not much lower than in the parallel cultures
treated with Bezielle continuously. These preliminary results
strongly support involvement of RIRR in the events triggered by
Bezielle. Moreover our unpublished results show that a transient, 2
to 4 hour treatment with Bezielle is sufficient to induce significant
death, not much lower than what was seen with a continuous
treatment with Bezielle for 24 hours. This is suggestive of the
possibility that the initial burst of ROS induced by Bezielle triggers
cellular changes that are irreversible, and depend on secondary
events such as RIRR that do not require further direct oxidative
damage by Bezielle.
This study analyzed the in vitro effects of Bezielle. It should be
recognized that the metabolic properties of tumor cells, ROS
dynamics, and the effects of Bezielle may differ in vivo, where
oxygen, pH, and nutrient conditions are different than those
encountered in cell culture. In particular, it would be of interest to
determine the effects of Bezielle under hypoxic conditions that are
frequently encountered in tumors. The published data showing
Bezielle’s anticancer activity in the in vivo tumor models, as well as
its promising efficacy in the clinical trials strongly suggest that
Bezielle has an antitumor activity in vivo, though the precise
mechanism of it might be somewhat different or more complex
that that observed in vitro.
Our study of Bezielle suggests that much if not all of Bezielle
selectivity towards tumor cells is based on the inherent differences
between mitochondria of tumor versus normal cells, in particular
in respect to their response to oxidative stress. This is important
because if the selective cytotoxicity of Bezielle relies on the intrinsic
differences between normal and tumor cells, this would make
Bezielle an excellent and safe anti-cancer drug. Clearly, differential
induction of ROS in tumor cells versus non-transformed cells is at
the heart of the selective cytotoxicity of Bezielle. This places
Bezielle in a group of drugs that selectively target mitochondria of
cancer cells, and that are now known as mitocans [38]. These
drugs comprise an emerging entity which generates much interest
not in the least due to their selectivity. Many of them are derived
from natural products [39] and are distinguished by low
cytotoxicity towards normal cells. The distinguishing feature of
Bezielle is that it simultaneously inhibits both OXPHOS and
glycolysis. These qualities and the selectivity of Bezielle towards
tumor cells are very encouraging for the further clinical
development of this drug.
Supporting Information
Figure S1 Time dependent increase in the generation of
peroxide type ROS (detected with DCFDA) in MDAMB231
and SKBr3 but not in MCF10A cells. Cells on 96 well plates
were first loaded with H2DCFDA, then incubated with Bezielle at
250 mg/ml. Fluorescence was measured at the times indicated.
Data are expressed as fold increase of fluorescence in Bezielle
treated cells compared to fluorescence of endogenous ROS in
untreated cells. Result are representative of one of the two
experiments.
(PDF)
Figure S2 A. Expression of NOX4 is increased in MDMB231
cells treated with Bezielle. Western blot analysis of MCF10A and
MDAMB231 cells treated with Bezielle for the indicated times. Cell
extracts were electrophoresed and blotted with antibodies against
NOX4 and GAPDH. B. Analysis of NOX4 expression in
MDAMB231 cells transduced with a control lentivirus encoding a
non-silencing sh RNA (consi) and lentivirus encoding a NOX4
shRNA. C. Generation of peroxide type ROS (detected with
DCFDA) and mitochondrial superoxide (MitoSox) in MDAMB231
cells with partially silenced NOX4 expression. D. Survival of control
and NOX4si cells after treatment with Bezielle. Results are average
of two experiments.
(PDF)
Figure S3 The proton production rates (PPR) undergo
changes very similar to ECAR (extracellular acidifica-
tion rates) in cells treated with Bezielle. A. Proton
production rate (PPR) is inhibited by Bezielle in tumor cell lines
MDAMB231 and Hs578T, but not in MCF10A. The results show
changes in PPR values in cells treated with BZL for 4 hours.
Significant differences (** P,0.01) between Bezielle treated and
untreated cells are indicated. B. Analysis of PPR in untreated
MDAMB231 cells or treated as described above. The data are
derived from the same metabolic flux experiments with the
Seahorse XF96 for which ECAR and OCR values are shown in
Figures 5A and B.
(PDF)
Figure S4 Mitochondria of tumor cells continue to
generate superoxide hours after Bezielle is removed.
MDAMB231 cells were treated with Bezielle for 1or 4 hours prior
to analysis, or treated for 1 hour and then incubated in fresh
medium without Bezielle for three hours (1+3 h).
(PDF)
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